In just a few short years, GLP-1 (Glucagon-Like Peptide-1) receptor agonists have moved from a specialist diabetes therapy to a cultural and economic force. What began as a metabolic treatment, a hormone that regulates blood sugar and appetite, has rapidly evolved into a mainstream intervention for chronic weight management — and in doing so, it is reshaping both the life sciences and consumer products industries. Below, our team unpacks how GLP-1 is impacting pharma and the food and beverage aisle.

The speed of adoption has been striking. While GLP-1 therapies have been used for type 2 diabetes for over a decade, newer formulations and expanded indications for obesity accelerated uptake dramatically beginning in 2021–2023. Weekly injectable semaglutide (marketed as Ozempic and Wegovy) and the dual-agonist tirzepatide (Mounjaro and Zepbound) delivered double-digit weight loss in large clinical trials, driving unprecedented patient demand. Prescriptions surged, payer policies evolved, and manufacturers scaled production to meet global interest.   

One side effect of the unprecedented growth was the rise of compounded GLP-1s, which are not approved by the FDA. These are unregulated drugs that aren’t fully reviewed for effectiveness or safety and can introduce quality concerns. Manufacturers like Novo Nordisk have been pushing back, but it has added a complex element to a highly demanded therapy.   

At the same time, dosing strategies have matured. Rather than rushing patients to higher doses, providers are taking a more gradual approach to reduce side effects and help patients stay on therapy over time. Maintenance dosing is becoming more personalized, balancing efficacy with tolerability. What began as rapid adoption is now transitioning into a longer-term conversation about sustained use, adherence, and safety monitoring.  

Health Implications: A Broader Therapeutic Footprint 

GLP-1 therapies began as treatments for type 2 Diabetes, but their clinical utility has expanded rapidly. What started with glycemic control evolved into chronic weight management and has since extended into additional cardiometabolic and organ-specific indications. 

Today, one or more GLP-1 therapies carry FDA approvals for: 

• Chronic weight management, addressing obesity and related health conditions. 
• Cardiovascular risk reduction, including evidence that these therapies lower the risk of serious cardiac events such as heart attack and stroke. 
• Chronic Kidney Disease risk reduction in patients with type 2 diabetes. 
• Obstructive sleep apnea, expanding treatment options for obesity-related respiratory conditions. 
• Metabolic Dysfunction–Associated Steatohepatitis (MASH), marking a significant advancement in liver disease management.  

These approvals signal a shift. GLP-1 therapies aren’t viewed solely as glucose-lowering or weight-loss agents but increasingly positioned as foundational cardiometabolic and organ-protective therapies with multi-system impact.  

At the same time, rapid weight loss has sparked new beauty-related considerations, from changes in facial volume to shifts in overall body composition. These changes are contributing to increased interest in skin tightening treatments and body contouring procedures. While not treatment goals, these ripple effects underscore how metabolic therapies are blurring traditional industry boundaries, influencing demand across healthcare, beauty, wellness, and broader consumer markets. 

The therapeutic footprint of GLP-1 medications is broadening, as these drugs have evolved into catalysts reshaping health behaviors, expectations, and long-term wellness strategies. As a result, clinicians and patients are observing benefits that extend beyond weight loss, which is influencing cultural discourse and adjacent industries. 

From Physiology to Purchasing Power: Where Life Sciences Meets the Aisle 

The expanding clinical impact of GLP-1 therapies is also a behavioral story. When appetite regulation shifts, daily routines tend to shift with it. Many patients report eating fewer meals, reducing snacking frequency, and prioritizing nutrient-dense, protein-forward foods to feel satisfied with smaller portions. Over time, these micro-behavioral changes add up. 

For life sciences organizations, this highlights the importance of long-term monitoring, patient education around muscle preservation and micronutrient sufficiency, and continued evaluation of dosing strategies and safety signals. 

For consumer products companies, the implications are just as profound. If millions of consumers eat smaller portions, snack less frequently, seek higher protein and nutritional function, and reevaluated indulgence occasions, then category demand curves begin to move. 

Early signals suggest potential pressure on calorie-dense snack foods, sugary beverages, and certain impulse categories — including alcohol— as consumers on GLP-1 therapies often report reduced desire for alcohol and lower consumption levels, potentially reshaping spending in on-premise and off-premise alcohol channels. Growth opportunities are also emerging in protein-rich products, hydration, portion-controlled packaging, fresh offerings, and functional formulations aligned with wellness goals. 

We’re already seeing signs of this recalibration. Some large snack manufacturers have noted softer volume trends in certain indulgent categories. Restaurant and retail players are leaning more heavily into higher-protein, nutrient-dense options. Chipotle has emphasized protein-forward bowls and customizable portion strategies that align with consumers seeking satiety with fewer calories. Starbucks has expanded its ready-to-drink and in-store protein beverage offerings. Across grocery aisles, brands are reformulating around higher protein content, functional ingredients, and smaller pack sizes that reflect changing consumption patterns. 

This is not a collapse of consumption. It’s a recalibration.  

And it is here that the intersection of life sciences and consumer products becomes critical. 

GLP-1 Impact: Life Sciences & Consumer Products  

Historically, pharmaceutical innovation and food category strategy operated in parallel. Today, they are converging. Medications are influencing eating behavior at scale. Consumer brands are responding with reformulation, resizing, and repositioning. Health systems, telehealth platforms, and retail ecosystems are increasingly interconnected around shared consumers. 

Clarkston’s immersion in both industries provides a distinct vantage point. We see not only the clinical adoption curves and regulatory milestones shaping GLP-1 deployment and tangential therapies such as MASH but also the downstream implications for portfolio strategy, supply chain planning, product innovation, and consumer segmentation.   

The companies best positioned to thrive will move beyond reaction. Life sciences organizations must plan for sustained utilization, expanded indications, and integrated care models. Consumer products companies must model long-term demand scenarios, innovate around satiety and nutrient density, and reimagine how their brands support evolving health behaviors. 

GLP-1 adoption represents a structural shift in how consumers experience hunger, manage health, and make purchasing decisions. In this moment of convergence, strategy demands a cross-industry lens.